infectious disease

UK health officials are widening the MenB response in Kent by offering second doses to people already given a first shot, after an outbreak that has left two people dead and 21 confirmed cases.

Phase 3 PreVenTB trial of 12,717 people across India shows VPM1002 cuts extrapulmonary tuberculosis by 50%, but neither candidate prevents pulmonary TB or latent infection.

Researchers at the University of California San Diego have developed pPro-MobV, a second-generation CRISPR-based gene drive that spreads through bacterial populations via conjugal transfer to disable antibiotic resistance genes, demonstrating effectiveness even within biofilms.

Two Phase 3 ARTISTRY trials show bictegravir/lenacapavir maintains viral suppression while replacing regimens of up to 11 daily pills with one tablet.